Mission Therapeutics

Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by mitochondrial dysfunction.

By targeting a mitochondria-localised DUB, the company's drug candidates are designed to enhance mitophagy, the cellular process that removes damaged mitochondria, promoting cell and organ health.

Its clinical pipeline addresses Parkinson's disease, acute kidney injury, and Duchenne muscular dystrophy, with candidates currently in Phase I and Phase II trials.